Product Review: Breztri Aerosphere® for maintenance treatment of COPD

This publication is intended as an educational resource for health professionals. It discusses the evidence for the use of budesonide/glycopyrronium/formoterol metered aerosol inhaler [Breztri Aerosphere®] for maintenance treatment in adults with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) who require treatment with a combination of an inhaled corticosteroid (ICS), a long-acting beta-2-adrenergic agonist (LABA), and a long-acting muscarinic antagonist (LAMA).* Breztri Aerosphere has been proven to ease symptoms and exacerbations, improve lung function and quality of life, and reduce all-cause mortality in individuals with moderate-to-very severe COPD. Furthermore, Breztri Aerosphere is generally well tolerated with a tolerability profile similar to its individual agents. Breztri Aerosphere has been funded since 1 January 2025 for the treatment of moderate-to-very severe COPD in individuals who are using two or three inhalers daily and meet certain clinical criteria (Breztri Aerosphere Application for Subsidy by Special Authority).

​This publication has been commissioned and funded by AstraZeneca. The content is based on published studies and the author’s opinions and may not reflect the views of AstraZeneca. Please consult the full Data Sheet for any medications mentioned in this article at www.medsafe.govt.nz before prescribing. Treatment decisions based on these data are the full responsibility of the prescribing physician.
* In New Zealand, Breztri Aerosphere is not indicated for the initiation of therapy in COPD